The decision to no longer seek approval of amlitelimab is the latest setback for a treatment once hailed as a future blockbuster. One analyst expects Sanofi to now pursue “strategic action” to boost its pipeline.
An article from
Dive Brief
The decision to no longer seek approval of amlitelimab is the latest setback for a treatment Sanofi once hailed as a future blockbuster.
Published July 24, 2026
Courtesy of Sanofi
Sanofi has decided it won’t seek an approval in atopic dermatitis for amlitelimab, the OX40-ligand antibody it had hoped would be…
Sanofi discontinued amlitelimab for atopic dermatitis after reviewing phase 3 efficacy and safety data, ending plans for…
Sanofi has discontinued clinical development of amlitelimab, an OX40 inhibitor, for the treatment of moderate to severe atopic…
The failure adds to a series of mixed or negative readouts and leaves in doubt the future of a therapy Sanofi has viewed as a…
Sanofi books over €1B in Q2 impairment charges axing amlitelimab, balinatunfib and itepekimab, and upgrades 2026 sales guidance…
Company returned about €390 million to shareholders in the past five years as it sold down investments
Sanofi discontinues amlitelimab development, citing lack of meaningful eczema benefit
